Q&A with ProQuest and Pi2 - Literature Monitoring in Drug Safety
Jinfo Article
20th October 2015
Abstract
We interviewed ProQuest and Pi2 management to find out more about the value of Pi2 to ProQuest's corporate pharmaceutical customers, how it helps drug safety departments to cope with increasing workloads and what makes for most effective literature monitoring in drug safety.
Content Access
Access to Jinfo Content and Community is available through a Jinfo Subscription.
Does your organisation have a Jinfo Subscription?
"Not yet"
Access to this article is available through a Jinfo Subscription, which will help your organisation:
- Save time and money
- Re-invent information services
- Define, measure and communicate information value.
"Don't know"
Contact us to find out if your organisation already has a Jinfo Subscription.
Or use the 'Text Chat' button at the bottom-right of this page for immediate assistance.
- Article title: Q&A with ProQuest and Pi2 - Literature Monitoring in Drug Safety
- Link to this page
- View printable version
Related articles:
- Q&A with Eduserv - Authentication in the Information Industry
Monday, 19th October 2015 - Q&A with CLA - Copyright Compliance in Multinational Business
Tuesday, 6th October 2015
Related Blog items:
- Are You Prepared for the Future of Corporate Information?
Wednesday, 30th September 2015
Vendor adoption of AI
Community session
23rd May 2024
Mainstream GenAI, emerging vendors and your offshore resourcing strategy
Blog posting
9th May 2024
May 2024 Update
YouTube video
9th May 2024
- Jinfo Community session (TBC) (Community) 16th July 2024
- Jinfo Community session (TBC) (Community) 20th June 2024
- Vendor adoption of AI (Community) 23rd May 2024